Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. Before joining Xconomy, he was the national biotechnology reporter for Bloomberg News, based in San Francisco. There, he led coverage of major medical meetings like the American Society of Clinical Oncology and broke news about the industry’s top companies, including Amgen, Genentech, and Biogen Idec. His stories appeared in The New York Times, Los Angeles Times, and International Herald Tribune. From 2001 to 2006, his passionate coverage of the biotechnology industry won many awards for The Seattle Times.
While at the Times, Luke was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award, the Sigma Delta Chi prize from the Society of Professional Journalists, an honorable mention Gerald Loeb Award, and was nominated for the Pulitzer Prize in public service.
Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison. In 2005-2006, he was a Knight Science Journalism Fellow at MIT. In his spare time, Luke runs marathons, climbs mountains and roots for the Green Bay Packers.
-
Ion Torrent Systems, a company advised by Harvard University genomics pioneer George Church, has raised $23 million in new capital to develop what it calls on its website “groundbreaking... Read more »
-
RXi Pharmaceuticals (NASDAQ: RXII), the Worcester, MA-based developer of RNA interference drugs, said today that Noah Beerman has replaced Tod Woolf as president and CEO. Beerman, 47, was most recently... Read more »
-
Gloucester Pharmaceuticals has won clearance to start selling its first cancer drug in the U.S.
The Cambridge, MA-based biotech company said today it has gotten the green light from the FDA... Read more »
-
Light Sciences Oncology, the Bellevue, WA-based developer of an unusual drug-device combo treatment for cancer, has put itself in position to raise $35 million for its product development through setting up... Read more »
-
The local life sciences scene was pretty quiet this week, although we heard more than usual from medical device companies.
—Paul Yager, the University of Washington’s chair of bioengineering, offered a... Read more »
-
I’m dashing this message off right before I get on a plane for Xconomy’s big event tomorrow afternoon: “Pharma’s Bet on Boston Innovation.” Only a few tickets are left... Read more »
-
Cambridge, MA-based Ironwood Pharmaceuticals has some new evidence out this morning that its lead drug candidate is an effective treatment for patients with chronic constipation.
Ironwood and its partner, New York-based... Read more »
-
When somebody gets a fever in a poor country, there is no quick or easy way to tell whether it’s a symptom of flu, malaria, a bacterial invader, or some other... Read more »
-
The Seattle-based Institute for Systems Biology and Mountain View, CA-based Complete Genomics said today they are planning to gather full human genome sequences from 100 individuals to study Huntington’s disease. The... Read more »
-
Seattle-based Dendreon said today it has completed all the necessary paperwork for its lead drug candidate, and handed over the amended application for approval to the FDA. The company had told... Read more »
-
Pulmatrix, the Lexington, MA-based company working to stop infectious bugs from being absorbed into the lungs, has raised $30.2 million in a Series B venture round to advance its unorthodox... Read more »
-
The leading edge of innovation in medical devices is often concentrated on nifty implantable tools that a doctor can insert without a scalpel, as a less-invasive alternative to surgery. But now... Read more »
-
San Diego-based Amylin Pharmaceuticals, the dark horse in the race to develop a new breed of weight-loss drugs, has struck a partnership with Japan-based Takeda Pharmaceuticals that could be worth more... Read more »
-
Vertex Pharmaceuticals wants to make sure doctors walk away from this weekend’s big liver disease research meeting with two main ideas stuck in their heads. No. 1—The company’s experimental drug is... Read more »
-
San Diego-based Amylin Pharmaceuticals (NASDAQ: AMLN) and its partner Eli Lilly got some positive news late Friday from the FDA. The agency now says the companies have clearance to market... Read more »
-
[Update: 7:15 pm Eastern, 10/30/09] Cambridge, MA-based Cequent Pharmaceuticals, one of the many aspiring firms in the field of RNA interference drug technology, has raised $3.35 million in... Read more »
-
Shares of Cambridge, MA-based Idenix Pharmaceuticals plummeted in early trading this morning after Novartis declined an option to further develop an Idenix drug for the liver disease hepatitis C.
Idenix (NASDAQ:... Read more »
-
Money may be tight for aspiring cleantech entrepreneurs in a downturn, but they got a little cash and some precious attention for their ideas last night. Gov. Chris Gregoire showed up... Read more »
-
Isis Pharmaceuticals (NASDAQ: ISIS) likes to talk about how its gene-silencing technology known as antisense creates so many innovative ideas for new drugs that it can’t commercialize them all itself,... Read more »
-
We had a little something for everybody on the life sciences beat this week, with news on biopharmaceuticals, devices, and healthcare software.
—Seattle-based Omeros (NASDAQ: OMER) had potential to be... Read more »
